Title: Interleukin-4 Receptor
Additional Names: IL-4R
Literature References: Endogenous receptor for interleukin-4, q.v., expressed on the surface of B and T lymphocytes, mast cells and macrophages, that mediates the bioactivities of the cytokine. mol wt ~140 kDa. Also secreted as a soluble, truncated form (sIL-4R) which lacks the transmembrane and intracellular domains and is capable of binding and sequestering circulating IL-4. Identification of membrane bound receptors: J. Ohara, W. E. Paul, Nature 325, 537 (1987). Characterization of murine: L. S. Park et al., Proc. Natl. Acad. Sci. USA 84, 1669 (1987); of human: idem et al., J. Exp. Med. 166, 476 (1987). Cloning of murine and identification of soluble form: B. Mosley et al., Cell 59, 335 (1989). Detection of sIL-4R in biological fluids: R. Fernandez-Botran, E. S. Vitetta, Proc. Natl. Acad. Sci. USA 87, 4204 (1990). Immunoregulatory effects of recombinant sIL-4R: C. R. Maliszewski et al., Proc. Soc. Exp. Biol. Med. 206, 233 (1994). Review of signaling mechanisms of membrane receptor: A. D. Keegan et al., Immunol. Today 15, 423-432 (1994). Review of bioactivity and therapeutic potential of sIL-4R: K. Enssle et al., Behring Inst. Mitt. 96, 103-117 (1995).
Derivative Type: Altrakincept
CAS Registry Number: 239076-74-5
Additional Names: Recombinant human soluble interleukin-4 receptor
Trademarks: Nuvance (Immunex)
Literature References: Soluble form of the human IL-4 receptor produced by recombinant DNA technology in Chinese hamster ovary cells. Glycoprotein; mol wt 54 kDa. Prepn: D. J. Cosman et al., EP 367566; B. Mosley et al., US 5599905 (1990, 1997 both to Immunex). Clinical evaluation in atopic asthma: L. C. Borish et al., Am. J. Respir. Crit. Care Med. 160, 1816 (1999). Review: R. Lange, Curr. Opin. Cardiovasc. Pulm. Renal Invest. Drugs 1, 526-531 (1999).
Therap-Cat: Soluble form as antiasthmatic. |